Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 4/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645678 | 0.86 | AKT1 (0.48) | AKT1PDE2AAKT2BTKCNR1 | |
| SCHEMBL17660339 | 0.85 | AKT1 (0.34) | AKT1PRMT1PDE2AMAP4K4CCNT1 | |
| SCHEMBL4093183 | 0.76 | MAPT (0.45) | AKT1PDE2AALOX5RORCMEN1 | |
| SCHEMBL4087871 | 0.73 | AKT1 (0.43) | AKT1PDE2AAKT2CNR1CNR2 | |
| SCHEMBL28590955 | 0.73 | BTK (0.43) | BTKMEN1MAPTKMT2A | |
| SCHEMBL30950456 | 0.72 | BTK (0.40) | BTK | |
| SCHEMBL17660343 | 0.72 | BTK (0.40) | BTK | |
| SCHEMBL1141689 | 0.72 | AKT1 (0.36) | AKT1PDE2AAKT2CNR1CNR2 | |
| SCHEMBL17109514 | 0.72 | MAPT (0.43) | AKT1PDE2AAKT2ALOX5RORC | |
| SCHEMBL25156379 | 0.71 | AKT1 (0.51) | AKT1PDE2AAKT2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | AKT1 209/4885PRMT1 2675/4885PDE2A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.